uniQure (NASDAQ:QURE) CFO Christian Klemt sold 2,400 shares of uniQure stock in a transaction dated Tuesday, September 21st. The stock was sold at an average price of $38.00, for a total transaction of $91,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of NASDAQ:QURE opened at $37.87 on Thursday. The firm’s 50 day moving average price is $30.46 and its 200-day moving average price is $32.03. uniQure has a twelve month low of $25.80 and a twelve month high of $52.19. The company has a quick ratio of 15.06, a current ratio of 15.06 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $1.74 billion, a PE ratio of 5.94 and a beta of 1.22.
uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Sunday, July 25th. The biotechnology company reported $8.51 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.97 by $5.54. uniQure had a net margin of 60.66% and a return on equity of 90.98%. The firm had revenue of $463.87 million for the quarter, compared to analysts’ expectations of $212.65 million. Analysts expect that uniQure will post 6.23 earnings per share for the current fiscal year.
Several equities analysts have recently weighed in on the stock. Credit Suisse Group reiterated an “outperform” rating and issued a $27.46 target price (down previously from $78.00) on shares of uniQure in a research note on Tuesday, July 27th. Chardan Capital reiterated a “buy” rating and issued a $95.00 target price (down previously from $100.00) on shares of uniQure in a research note on Tuesday, July 27th. Zacks Investment Research raised shares of uniQure from a “sell” rating to a “hold” rating in a research note on Friday, July 30th. BTIG Research began coverage on shares of uniQure in a report on Monday, June 14th. They issued a “buy” rating and a $46.00 price objective for the company. Finally, SVB Leerink restated a “buy” rating on shares of uniQure in a report on Tuesday, September 14th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, uniQure currently has an average rating of “Buy” and an average price target of $59.95.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.